The short version of LY3437943 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
== Bibliography == Balaban, Naomi (2008). The Handy Anatomy Answer Book. Visible Ink Press. ISBN 978-1-57859-190-9. Barnes, Edward E.; Fox, Richard S.; Barnes, Robert D. (2003). Invertebrate zoology : a functional evolutionary approach (7. ed.). Belmont, Calif. [u.a.]: Thomson, Brooks/Cole. ISBN 0-03-025982-7. Forbes, R. M.; Mitchell, H. H.; Cooper, A. R. (1956). "Further studies on the gross composition and mineral elements of the adult human body". Journal of Biological Chemistry. 223 (2). American Society for Biochemistry and Molecular Biology: 969–975. doi:10.1016/S0021-9258(18)65095-1. PMID 13385244. Mish, Frederick C., ed. (2003). Merriam-Webster's Collegiate Dictionary (11th ed.). Merriam-Webster. ISBN 978-0-87779-807-1. Nasoori, Alireza (2020). "Formation, structure, and function of extra-skeletal bones in mammals". Biological Reviews. 95 (4). Cambridge Philosophical Society: 986–1019. doi:10.1111/brv.12597. PMID 32338826. S2CID 216556342. Pechenik, Jan A. (2015). Biology of the Invertebrates (7th ed.). McGraw-Hill Education. ISBN 978-0-07-352418-4. Reynolds, William W.; Karlotski, William J. (1977). "The Allometric Relationship of Skeleton Weight to Body Weight in Teleost Fishes: A Preliminary Comparison with Birds and Mammals". Copeia. 1977 (1). American Society of Ichthyologists and Herpetologists: 160–163. doi:10.2307/1443520. JSTOR 1443520. Ruppert, Edward E.; Fox, Richard S.; Barnes, Robert D. (2003). Invertebrate Zoology (7th ed.). Thomson, Brooks/Cole. ISBN 978-0-03-025982-1. Stein, Lisa (2007). Body: The Complete Human. National Geographic Society.
To come up with these criteria, BioSHaRE controlled for age and tobacco use, researching how both may effect the metabolic syndrome associated with obesity, but not found to exist in the metabolically healthy obese. Other definitions of metabolically healthy obesity exist, including ones based on waist circumference rather than BMI, which is unreliable in certain individuals. Another identification metric for health in obese people is calf strength, which is positively correlated with physical fitness in obese people. Body composition in general is hypothesized to help explain the existence of metabolically healthy obesity—the metabolically healthy obese are often found to have low amounts of ectopic fat (fat stored in tissues other than adipose tissue) despite having overall fat mass equivalent in weight to obese people with metabolic syndrome.
In the second cycle, glyoxylate is approximately one equivalent of propionyl-CoA forming methylamalonyl-CoA. This, in turn, is then converted through a series of reactions into citramalyl-CoA. The citramalyl-CoA is split into pyruvate and acetyl-CoA thanks to the enzyme MMC lyase. The pyruvate is released at this point, while the acetyl-CoA is reused and carboxylated again at malonyl-CoA, thus reconstituting the cycle. A total of 19 reactions are involved in the 3-hydroxypropionate bicycle, and 13 multifunctional enzymes are used. The multi-functionality of these enzymes is an important feature of this pathway which thus allows the fixation of three bicarbonate molecules. It is a costly pathway: 7 ATP molecules are consumed to synthesise the new pyruvate and 3 ATP for the phosphate triose. An important characteristic of this cycle is that it allows the co-assimilation of numerous compounds, making it suitable for the mixotrophic organisms.
These relations between penis size and attractiveness have therefore led to frequently emphasized associations between masculinity and penis size in popular media. This has led to a social bias existing around penis size with larger penises being preferred and having higher social status. This is reflected in the association between believed sexual prowess and penis size and the social judgement of penis size in relation to 'manhood'.
=== Mechanisms === In vitro transcription (IVT) is performed on a linearized DNA plasmid template containing the targeted coding sequence. Then, naked mRNA or mRNA complexed in a nanoparticle will be delivered systemically or locally. Subsequently, a part of the exogenous naked mRNA or complexed mRNA will go through cell-specific mechanisms. Once in the cytoplasm, the IVT mRNA is translated by the protein synthesis machinery. There are two identified RNA sensors, toll-like receptors (TLRs) and the RIG-I-like receptor family. TLRs are localized in the endosomal compartment of cells, such as DCs and macrophages. RIG-I-like family is as a pattern recognition receptor (PRR). However, the immune response mechanisms and process of mRNA vaccine recognition by cellular sensors and the mechanism of sensor activation are still unclear.
Sources: en.wikipedia.org
Molybdenum forms chemical compounds in oxidation states −4 and from −2 to +6. Higher oxidation states are more relevant to its terrestrial occurrence and its biological roles, mid-level oxidation states are often associated with metal clusters, and very low oxidation states are typically associated with organomolybdenum compounds. The chemistry of molybdenum and tungsten show strong similarities. The relative rarity of molybdenum(III), for example, contrasts with the pervasiveness of the chromium(III) compounds. The highest oxidation state is seen in molybdenum(VI) oxide (MoO3), whereas the normal sulfur compound is molybdenum disulfide MoS2.
A Scanner Darkly is a science fiction novel by American writer Philip K. Dick, published in 1977. The semi-autobiographical story is set in a dystopian Orange County, California, in the then-future of June 1994, and includes an extensive portrayal of drug culture and drug use (both recreational and abusive). The novel is one of Dick's best-known works and served as the basis for a 2006 film of the same name, directed by Richard Linklater.
== Interaction with other cells == Within the epidermis keratinocytes are associated with other cell types such as melanocytes and Langerhans cells. Keratinocytes form tight junctions with the nerves of the skin and hold the Langerhans cells and intra-dermal lymphocytes in position within the epidermis. Keratinocytes also modulate the immune system: apart from the above-mentioned antimicrobial peptides and chemokines they are also potent producers of anti-inflammatory mediators such as IL-10 and TGF-β. When activated, they can stimulate cutaneous inflammation and Langerhans cell activation via TNFα and IL-1β secretion. Keratinocytes contribute to protecting the body from ultraviolet radiation (UVR) by taking up melanosomes, vesicles containing the endogenous photoprotectant melanin, from epidermal melanocytes. Each melanocyte in the epidermis has several dendrites that stretch out to connect it with many keratinocytes. The melanin is then stored within keratinocytes and melanocytes in the perinuclear area as supranuclear "caps", where it protects the DNA from UVR-induced damage.
== Function == While the whole hCG glycoprotein hormone is a heterodimer consisting of an alpha and a beta subunit, it is the beta subunit alone that is responsible for the specificity of function of hCG. Thus, in this section, we will be referring to hCG as the specific beta subunit CGB, due to the subunit being solely responsible for its relevant function in pregnancy. CGB is only produced by the human body during pregnancy. CGB is the very first specific molecule synthesized by the embryo, with its RNA transcribed as early as the eight-cell stage. It is the trophoblast, which is the outer layer of the blastocyst, that first synthesizes this glycoprotein hormone. The blastocyst will become the embryo, and the trophoblast will eventually become part of the placenta. The blastocyst/trophoblast release CGB into the uterine space, which is somehow able to reach the hCG/LH receptor on the endometrial surface. Again, it is specifically the beta subunit of hCG (and also LH) that binds to the receptor, as the alpha subunits of both hormones, as well as FSH and TSH, are the same. This nonvascular communication by CGB is highly remarkable, and it is still not fully understood how CGB is able to communicate with the endometrial surface without being attached to it. Binding of CGB to the hCG/LH receptor prepares the endometrium for the impending implantation of the blastocyst. CGB implements immunotolerance and angiogenesis at the endometrial maternal-fetal interface, which is particularly critical to the establishment of a successful pregnancy.
Sources: en.wikipedia.org
is the speed of light in vacuum. Typical metals that support surface plasmons are silver and gold, but metals such as copper, titanium or chromium have also been used. When using light to excite SP waves, there are two configurations which are well known. In the Otto configuration, the light illuminates the wall of a glass block, typically a prism, and is totally internally reflected. A thin metal film (for example gold) is positioned close enough to the prism wall so that an evanescent wave can interact with the plasma waves on the surface and hence excite the plasmons. In the Kretschmann configuration (also known as Kretschmann–Raether configuration), the metal film is evaporated onto the glass block. The light again illuminates the glass block, and an evanescent wave penetrates through the metal film. The plasmons are excited at the outer side of the film. This configuration is used in most practical applications.
10 October – The Scottish Government shelves plans for the early release of long term prisoners following concerns raised by victims groups, but will reduce the automatic early release for short term prisoners from the point of 50% completion of their sentence to 40%. 11 October – It is reported that Education Secretary Jenny Gilruth has withheld £145.5m in funding to all councils because of a disagreement over cuts to the number of teachers. 12 October – Alex Salmond, former first minister of Scotland, dies aged 69 in North Macedonia. 13 October – Flags are lowered to half-mast at the Scottish Parliament following the death of former First Minister Alex Salmond the previous day. MSP John Mason is expelled from the SNP after posting on Twitter that there was "no genocide" in Gaza. 14 October – The Scottish Government confirms that ferry fares in Scotland will increase by 10% from 1 January 2025. Glasgow City Council unveils plans to make improvements to the city centre, with the changes scheduled to begin in 2025. 16 October – Following trial and conviction at the High Court in Edinburgh, Jamie Boulton is sentenced to life imprisonment with at least 18 years in custody for the stabbing murder of Gary O'Neill at a flat in Leith in June 2023. 17 October – BBC One programme Crimewatch Live makes a fresh appeal for information leading to the discovery of the remains of Suzanne Pilley, who was murdered by her ex-partner in 2010.
In 1970, lithium was approved by the United States Food and Drug Administration for the treatment of bipolar disorder, which remains its primary use in the United States. It is sometimes used when other treatments are not effective in a number of other conditions, including major depression, schizophrenia, disorders of impulse control, and some psychiatric disorders in children. Because the FDA has not approved lithium for the treatment of other disorders, such use is off-label. Lithium is unique among medications in that it is proven to prevent suicide in mood disorders such as bipolar disorder and recurrent major depression. The mechanisms of biological action of lithium are only partially understood. For instance, studies of lithium-treated patients with bipolar disorder show that, among many other effects, lithium partially reverses telomere shortening in these patients and also increases mitochondrial function, although how lithium produces these pharmacological effects is not understood. High blood levels of lithium can lead to lithium toxicity.
=== Position of Tantulocarida === According to Petrunina A.S. and Kolbasov G.A., the sixth subclass of Maxillopoda Tantulocarida may lie within Thecostraca, forming a clade with thecostracan infraclass Cirripedia (if so, Thecostraca excluding Tantulocarida is paraphyletic):
=== Mass spectrometry === Ion funnels are frequently used in mass spectroscopy devices to collect ions from an ionization source. Previous devices lacking an ion funnel often lost ions during the transition from ionization source to the detector of the mass spectrometer. This loss was due to the increasing number of collisions undergone by ions with other gas molecules present in the atmosphere. The introduction of the ion funnel greatly reduced the amount of ions lost during experiments by guiding ions towards a desired destination, and through modification of the number of inlets is also able to increases sensitivity of measurements taken by the mass spectrometer. Multiple inlets allow multiple electrospray emitters, reducing the flow through each individual emitter. This creates many highly efficient electrosprays at low flow rates. Multiple inlets also improve sensitivity, with a linearly arranged 19 electrospray emitter coupled to 19 inlets operating at 18 Torr giving a nine-fold increase compared to a single inlet.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.